Dasatinib, an Src inhibitor, and oxaliplatin are approved by the Food and Drug Administration (FDA) for treating chronic myeloid leukemia (CML) (ClinicalTrials.gov identifier: NCT01460160) and colon cancer (ClinicalTrials.gov identifier: NCT00017082), respectively. This evidence concerns the gene SRC and malignant colon neoplasm.